Davis Corley.

DALLAS—Neurolens, based here, has announced a strategic leadership restructure. The new structure combines seasoned leadership with strategic hires. In December, company co-founder Davis Corley returned as CEO. Davis led the company from early-stage development to full commercialization. “As co-founder of Neurolens, I was able to guide the direction of our organization, working with an incredible leadership team to bring real change to our industry,” Davis said in a statement that was released by Neurolens.

“As we start the next phase of transforming eyecare, stepping back into the role of CEO was a natural fit. Being on this journey for the past 12 years, I can confidently say the most exciting chapter of Neurolens' story is right in front of us.”

Davis’ return as CEO follows a $45 million capital investment in Neurolens by Trinity Capital Inc. (NASDAQ: TRIN), reported by VMAIL in December, as well as the recent departure of Pierre Bertrand, who has served as president for the past five years. Bertrand has joined Sanitas Advisors as a strategic advisor.

Filling out the Neurolens management team is Gregory Boisse, senior vice president, operations; Nathan Schomas, senior vice president of digital innovation; Bill Kastein, vice president, strategic partnerships and business development; Kelly Vaupel, vice president of marketing; and Eric Patnode, vice president of leadership, learning and development. Zach Dios drives product innovation as vice president of engineering.

Danny Perales remains chief financial office and chief operating officer, Kaelin Currie remains vice president of lab operations and Stéphane Arcand remains vice president, Canada.

Neurolens also announced two new hires: Katrina Forinash, chief of staff, and Chris Cahill, vice president of accounting and finance.

Neurolens offers the only prescription lenses that use a contoured prism to treat headaches, neck and shoulder pain, and eyestrain caused by eye misalignment. The company recently announced the launch of the N3, a fast and accurate way for eyecare providers to measure eye misalignment down to a fraction of a prism diopter.